Sens. Richard Blumenthal (D-Conn.) and Bob Corker (R-Tenn.) introduced a bill in the Senate that would provide incentives to drug companies to develop antibiotics that fight antibiotic-resistant bacteria.
Bill aims to aid fight against drug-resistant germs
The Generating Antibiotic Incentives Now Act aims to address the rise of antibiotic-resistant infections, which are a cause of $26 billion in extra costs for the healthcare system each year, according to a news release from Blumenthal's office. The legislation also intends to streamline the regulatory process by fast-tracking the Food and Drug Administration's review of innovative antibiotic drugs.
In June, Rep. Phil Gingrey (R-Ga.) introduced the GAIN Act. One element of the bill would extend market exclusivity of a new “qualified infectious disease product” by five years.
“Without putting any federal dollars at stake, our bill provides meaningful market incentives to encourage development of new antibiotics that will help save lives and reduce healthcare costs,” said Corker in the news release. “By strengthening this segment of the market that currently has only a handful of new drugs in the pipeline, we can help ensure Americans at home and our troops abroad have access to treatments capable of combating these deadly infections.”
The National Military and Veterans Alliance, the American Medical Association, and Children's National Medical Center have endorsed the legislation, according to the news release.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.